... paid for analyses for industry, including Eli
Lilly and Company. All authors are employees of ICNARC.
Authors' contributions
KR conceived the study. EN coordinated the study. CW and
DH performed ... manuscript. KR
had full access to all of the data in the study and takes responsibility for
the integrity of the data and the accuracy of the data analysis.
Ref...
... that
they have no competing interests.
Authors' contributions
HS and DNN conceived the study, and analyzed, interpreted and integrated
the data. They also elaborated the manuscript. JT and ... manuscript. JT and LH performed and
supervised the enrolment of patients in the study. JS performed the S100B
assay. All authors read and approved the final version of...
... for ADDRESS and PROWESS of 18.17% and 81.83%, respectively; method 2, a random effect model demonstrating a risk ratio using
weights for ADDRESS and PROWESS of 45.35% and 54.65%, respectively; ... R, Levy H, Talwar D, Trzaskoma BL,
Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al., for the
Administration of Drotrecogin alfa (activated) in Early Stage
Severe Sepsis (ADDRESS...
... other
cytokines (e.g. IL-8, IL-6, and leukotriene inhibitory factor),
proteases, and prostaglandin E
2
(PGE
2
) [30]. Synthesis of
the inflammatory cytokines IL-1 and TNF-α and expression
of their ... chondrocytes or
the articular cartilage surface in OA [29,31]. The activity of
many MMPs increases in OA by either an increase in their
own synthesis, an increased activation by th...
... NoNoNoNoYesNoNoNoYesNo
DrotAA-related
2
YesNoNoNoYesYesNoYesNoNo
Disease category
PF Yes Yes No No No Yes Yes No Yes Yes
MEN No No Yes Yes Yes Yes No Yes Yes No
MD YesNoYesNoNoYesNo NoNoYes
Baseline ... infusion
Day of event
1
117810UDUD
Bleeding event
ICH No No No Yes No Yes Yes
Fatal No No No Yes No Yes No
DrotAA related
2
No No No Yes No No No
Disease category
PF Yes Yes Yes Yes Yes No Yes...
... any case, we believe that
evidence for the routine use of DrotAA should be based on
consistent clinical trials and should not depend on the use of a
Letter
Drotrecogin alfa (activated): down and ... estimate of the effect of DrotAA for any
patient is the overall pooled result incorporating all patients.
Interestingly, although the degree of between-study hetero-
ge...
...
2001 the United States and European drug regulatory
agencies approved DrotAA for use in adult patients with
severe sepsis and high risk of death, as defined by an
Acute Physiology and Chronic ... greater in the DrotAA group both during the infusion
(2.4% vs. 1.2%, P=0.02) and in the 28-day study period
(3.9% vs. 2.2%, P=0.01) and were similar to rates seen in
the...
... uncertainty we used the extreme
estimates for both the most positive and the most negative
options for concomitant PPI therapy and NSAID use. The sec-
ond approach was used to show the impact of varying ... complication for the group using con-
comitant PPIs and the group not using concomitant PPIs.
To test the robustness of the results, two approaches were
used...
... malignancy and serious infection? Commentary on the
meta-analysis by Bongartz et al. Arthritis Res Ther 2006, 8:111.
Letter
Response to commentary by Dixon and Silman on the systematic
review and ... infliximab for partial responders [4]. Thus, not
only are our findings applicable to clinical practice and
biologically plausible, but they also fulfill the dose-effect
criterion...